Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract Virotherapy and checkpoint inhibitors can be combined for the treatment of cancer with complementarity and potential for synergistic effects. We have developed a cytolytic but non-replicative viral vector system based on Semliki Forest virus that encodes IL-12 (SFV-IL-12). Following direct intratumoral injection, infected cells release transgenic IL-12, die and elicit an inflammatory response triggered by both abundantly copied viral RNA and IL-12. In difficult to treat mouse cancer models, such as those derived from MC38 and bilateral B16-OVA, SFV-IL-12 synergized with an anti-PD-1 monoclonal antibody (mAb) to induce tumor regression and prolong survival. Similar synergistic effects were attained upon PD-L1 blockade. Combined SFV-IL-12 + anti-PD-1 mAb treatment only marginally increased the elicited CTL response over SFV-IL-12 as a single agent, at least when measured by in vivo killing assays. In contrast, we observed that SFV-IL-12 treatment induced expression of PD-L1 on tumor cells in an IFNγ-dependent fashion. PD-L1-mediated adaptive resistance thereby provides a mechanistic explanation of the observed synergistic effects achieved by the SFV-IL-12 + anti-PD-1 mAb combination. Citation Format: José I. Quetglas, Sara Labiano, M. Ángela Aznar, Elixabet Bolaños, Arantza Azpilicueta, Inmaculada Rodríguez, Erkuden Casales, Alfonso Rodríguez, Cristian Smerdou, Ignacio Melero. Virotherapy with a Semliki Forest virus-based vector encoding IL-12 synergizes with PD-1/PD-L1 blockade. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 281. doi:10.1158/1538-7445.AM2015-281

Original publication




Journal article


Cancer Research


American Association for Cancer Research (AACR)

Publication Date





281 - 281